EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization

Rinat Yerushalmi, Adi Pomerantz, Ron Lewin, Shani Paluch-Shimon, Lior Soussan-Gutman, Frederick L Baehner, Hillary Voet, Avital Bareket-Samish, Inbal Kedar, Yael Goldberg, Tamar Peretz-Yablonski, Luna Kadouri

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07271-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Rinat Yerushalmi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Davidoff Cancer Center, Rabin Medical Center, 39 Jabotinski St, 49414, Petah Tikva, Israel. rinaty@clalit.org.il. Hauptthemen laut MEDLINE: BRCA1 Protein, BRCA2 Protein, Mutation, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oncotest, Exact Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We compared 21-gene recurrence score (RS) distribution and expression of the single-gene/gene groups within this assay between BC patients with pathogenic variants (PV) in BRCA1/2 vs the general 21-gene-tested BC population.

Methods

This retrospective study included consecutive 21-gene-tested female ER + HER2-negative BC patients with germline PVs in BRCA1/2 . RS/gene expression data were compared to a previously described commercial use database (CDB, N = 799,986). Chi-square and 1-sample t test were used to compare RS distribution and single-gene/gene group scores between the study group and the CDB.

Results

Study group patients ( N = 81) were younger and their RS results were higher compared to the CDB (age: median [IQR], 56 [47–61.5] vs 60 [51–67] years; p < 0.001; proportion of patients with RS ≥ 26: 49.4% vs 16.4%, p < 0.001). Expression of 12/16 cancer genes in the assay and the ER, proliferation, and invasion gene group scores differed significantly between the study group and the CDB, all in a direction contributing to higher RS. The differences between the study group and the CDB were mostly retained, upon stratifying the patients by menopausal status.

Conclusion

BC patients with PVs in BRCA1/2 have higher RS results that stem from distinct gene expression profiles in the majority of genes in the 21-gene assay.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BRCA1 ProteinBRCA2 ProteinMutationGene Expression Regulation, NeoplasticBreast NeoplasmsRetrospective StudiesAntineoplastic AgentsTreatment OutcomeMenopauseHumansFemaleAdultMiddle AgedAged

Stichwörter der Autor:innen

21-gene assayBRCABreast cancerClinical outcomesPathogenic variantRecurrence Score

Substanzen

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 ProteinAntineoplastic Agents

Autor:innen und Institutionen

  • Davidoff Cancer Center, Rabin Medical Center, 39 Jabotinski St, 49414, Petah Tikva, Israel. rinaty@clalit.org.il.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. rinaty@clalit.org.il.
  • Davidoff Cancer Center, Rabin Medical Center, 39 Jabotinski St, 49414, Petah Tikva, Israel.
  • Radiation Oncology Dept, Sheba Medical Center, Ramat Gan, Israel.
  • Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel.
  • Faculty of Medicine, Hebrew University, Jerusalem, Israel.

Förderung

  • Oncotest
  • Exact Sciences

Zitieren

APA

Yerushalmi, R., Pomerantz, A., Lewin, R., Paluch-Shimon, S., Soussan-Gutman, L., Baehner, F. L., Voet, H., Bareket-Samish, A., Kedar, I., Goldberg, Y., Peretz-Yablonski, T., & Kadouri, L. (2024). BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07271-4

Vancouver

Yerushalmi R, Pomerantz A, Lewin R, Paluch-Shimon S, Soussan-Gutman L, Baehner FL, et al. BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07271-4

BibTeX
@article{Yerushalmi2024,
  author = {Yerushalmi, Rinat and Pomerantz, Adi and Lewin, Ron and Paluch-Shimon, Shani and Soussan-Gutman, Lior and Baehner, Frederick L and Voet, Hillary and Bareket-Samish, Avital and Kedar, Inbal and Goldberg, Yael and Peretz-Yablonski, Tamar and Kadouri, Luna},
  title = {BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07271-4}
}
Kostenlos starten →